Kidney Cancer Diagnostics Market

Kidney Cancer Diagnostics Market Outlook 2022-2032

The global kidney cancer diagnostics market is projected to expand steadily at a CAGR 7% value, during the forecast period 2022-2032. In the year 2022, the market size is projected to expand and gain a global market valuation of US$ 800 Million. Considering this increasing growth and the booming demand in the global market, the kidney cancer diagnostics market is expected to reach US$ 1.4 Billion by 2032.

Cancer diagnostics is the process of identifying biomarkers, enzymes, and other signs that can be used to detect a malignant tumor. Diagnostic testing is utilized to confirm or rule out illness, follow progression of the disease, and schedule and assess treatment outcomes. Cancer diagnostic procedures include imaging, laboratory tests (including tumor marker tests), tumor biopsy, endoscopic examination, genetic testing, and surgery.

Report Attributes	Details
Expected Market Value in 2022	US$ 800 Million
Projected Market Value in 2032	US$ 1.4 Billion
Global Growth Rate (2022-2032)	CAGR of 7%
Anticipated Market Share of the U.S Market (2022)	35%
Expected Growth Rate of the Chinese Market (2022-2032)	5.8% CAGR
Prominent Kidney Cancer Diagnostics Service Providers	Myriad Genetics Inc. NeoGenomics Laboratories NanoString Technologies Inc. Sysmex Corporation Rosetta Genomics Illumina Inc. Glenmark Cobolong Quest Diagnostics Incorporated Roche Holding AG Thermo Fisher Scientific Inc. Abbott Laboratories

Cancer diagnostics refers to the process of identifying many proteins, biomarkers, and symptoms that lead to the detection of the presence of a malignant tumor in a patient. The identification of certain proteins and biomarkers that are frequent in cancer disorders aids in the diagnosing procedure. The process of detecting cancer necessitates the employment of specialized technology and devices.

The market is largely driven by a rise in the frequency of kidney cancer and rising R&D spending by pharmaceutical firms. According to a research released in July 2021 by the International Kidney Cancer Coalition, over 431,000 persons worldwide are afflicted with kidney cancer each year.

Furthermore, according to the American Cancer Society 2022, around 431,328 people will be diagnosed with kidney cancer globally in 2022. As a result of the rising prevalence of kidney cancer, demand for kidney cancer therapies and diagnostics is predicted to rise throughout the forecast period.

2017-2021 kidney cancer diagnostics market Demand Analysis vs. Forecast 2022-2032

According to market research and competitive intelligence provider Fact.MR- the market for kidney cancer diagnostics reflected a value CAGR of 5.8% during the historical period, 2017- 2021. In recent years, the number of individuals living with kidney cancer has steadily climbed. Renal cancer has been shown to be more common in the elderly population, which is projected to fuel growth in the worldwide kidney cancer diagnostics market in the next few years and decades.

Several private organizations and government groups worldwide are attempting to increase awareness about kidney cancer. People's increased attentiveness and lifestyle changes are major factors driving market development. With the rising frequency of kidney cancer, future generations will benefit from more accessible, economical, and diagnosis-associated kidney cancer therapy. Technological advancements in equipment, increases in healthcare spending, and rising demand for blood chemistry testing for kidney cancer diagnostics are driving market expansion, which is predicted to grow at a 7% CAGR from 2022 to 2032.

Prominent Growth Drivers Influencing kidney cancer diagnostics market

Technological innovations to boost the global market demand

The medical device industry is a diversified, inventive, and fast-paced industry. From telemedicine to intelligent machines, robotic surgery, and 3D printing, technology is fast advancing and altering the healthcare business. Increased public and government expenditure in the healthcare sector, as well as rising demand for kidney cancer molecular diagnostics, are driving the market forward.

Improved versions of prominent diagnostic tools will almost definitely replace them. Governments throughout the world are taking various initiatives to boost kidney cancer detection systems, with an emphasis on R&D. Makers of kidney cancer diagnostic systems and healthcare providers have begun to provide tailored patient care for kidney cancer therapy, as well as access to entire end-to-end medical device goods and services. They are focusing on product prototype development and improvement, as well as minimizing operating expenses.

Due to developments in medical technology, the worldwide market for kidney cancer diagnostics is also projected to witness the launch of novel tests that may concurrently slow the pace of tumor formation between several stages of kidney cancer.

Novel Biomarkers for the Diagnosis of Kidney Cancer to boost Overall Productivity

Through enhanced detection technology and equipment, increasing understanding of some cancer biomarkers is generating a major business potential for treating cancer patients. Technological advances in the field of biotechnology have enabled the identification of potential cancer biomarkers, and some of these biomarkers have been commercialized. As a consequence, the development of new diagnostic biomarkers is opening up attractive potential for the growth of the cancer diagnostics market.

According to the study "The Early Diagnostic and Prognostic Value of BIRC5 in Clear-Cell Renal Cell Carcinoma Based on the Cancer Genome Atlas Data," published in the Karger Journal in April 2022, high BIRC5 expression is a key indicator of ccRCC prognosis, making BIRC5 an excellent biomarker for predicting patient prognosis in ccRCC. BIRC5 might be a good biomarker for detecting ccRCC early. As a result, the use of various techniques in the diagnosis of ccRCC cancer is likely to enhance the market, as the availability of such techniques may aid in the early detection of ccRCC cancer. Such benefits are expected to skyrocket the demand during 2022-2032.

What Could Possibly Hinder Kidney Cancer Diagnostics market Demand?

Surge in Treatment Costs will restrict Market Growth

Numerous regulatory investigations are necessary to get permissions, and as a result, moving discoveries from the discovery stage to the market for commercial usage is exceedingly expensive.

The vast majority of kidney cancer cases are discovered at a late stage. The severity of cancer and its diagnosis influence patients' and physicians' decisions to pay the high expense of therapy, even if the prognosis is only marginally better.

Over the projection period, the global cancer diagnostics market may face headwinds due to low clinical trial success rates and high costs. Such incidences if repeated during the forecast period, can stymie the growth.

Category-wise Insights

Which Test Type is forecast to gain the Maximum Market Share?

Immunohistochemistry will continue to dominate the Global Market

The immunohistochemistry category is expected to lead the global kidney cancer diagnostics market in 2022 and is likely to retain its dominance throughout the forecast period. The segment is predicted to gain a global market share of 65% by 2022. As immunohistochemistry is extensively used to identify kidney cancer and other disorders requiring antigen-antibody interactions, the rise in cancer incidence is a key driver driving market expansion. Immunohistochemistry is a microscopy method used to detect antigens and macromolecules contained in cells, as well as enzymes, tumor suppressor genes, antigens, and tumor cell proliferation.

Immunohistochemical methods are increasingly being used in the pathophysiology of renal neoplasms. Immunohistochemistry demand is increasing as a result of increased product approvals and the advent of immunohistochemistry solutions for kidney cancer detection. Demand for immunohistochemistry is predicted to rise in the next few years as a result of increased drug research and development activities, rising chronic illness prevalence, and an increase in the number of diagnostic facilities. Such incidences will propel the demand by 2x during the forecast period.

Will Hospital Associated Labs be Primary End Users of Kidney Cancer Diagnostics Services?

In 2022, the hospital-associated labs segment is expected to hold the major portion of the kidney cancer diagnostics market by type, accounting for almost 40% of the global market share. The burden of lowering the incidence of kidney cancer is carried on to hospitals and medical research groups as they try to create novel diagnostic and treatment approaches.

In hospital-affiliated labs, urine samples are submitted to specific tests to check for minute quantities of blood and other chemicals that aren't visible to the human eye. Growing use of devices in hospital-associated labs for the identification of kidney cancer and severe infections is predicted to fuel market growth over the next ten years.

Many hospitals are growing their capacity and adopting medical tools for kidney cancer diagnostics, and they've undertaken a range of tactics to get the required equipment, assure an adequate personnel, and upgrade their facilities and hence propel the market growth.

Country-wise Analysis

What is the Outlook of the U.S Kidney Cancer Diagnostics Market?

Rising Cancer Cases and increasing hospitalization rates will boost Market Demand

The U.S market will be the most lucrative market for kidney cancer diagnostics during the forecast period. As per Fact.MR, the US market is expected to gain a market share of 35% in 2022. According to GLOBOCAN 2020 figures, the expected number of kidney cancer cases in the USA was 60,347.

According to the American Cancer Society's projections for 2022, about 79,000 new cases of kidney cancer will be detected in the United States in 2022. The market in the United States is predicted to develop rapidly due to an increase in the number of patients with chronic illnesses, the frequency of kidney cancer, and the country's large number of healthcare facilities.

The availability of favorable reimbursement regulations, as well as high healthcare expenditure and recent breakthroughs in diagnostic instruments for transitional cell carcinoma renal cancer therapy, are projected to boost market growth in the United States. The market for kidney cancer diagnostics in the United States is predicted to grow 1.4x by 2032.

What can be expected from the Chinese market for kidney cancer diagnostics?

Increasing Consumer Awareness to boost Regional Demand

China has emerged as one of the most profitable markets for the marketing of kidney cancer diagnostics. Sales of kidney cancer diagnostic equipment are fast expanding in China. Growing patient awareness, decreasing medication manufacturing costs, and an increased patient base suffering from illnesses such as renal cell carcinoma are predicted to drive the Chinese market.

In China, where economic prospects are promising, companies are working on extending their product portfolios, diversifying their company operations, cutting costs, boosting customer contentment, and enhancing kidney cancer diagnostic reliability. According to Fact.MR's estimate, the Chinese kidney cancer diagnostics business is predicted to grow at a CAGR of roughly 5.8% between 2022 and 2032.

Start-up Scenario

• Klotho Therapeutics, located in the United States, creates recombinant versions of the human klotho protein to cure chronic kidney disease. In animal models, the solution was shown to greatly reduce the risk of chronic kidney disease (CKD) and acute renal failure (ARF). It also has the potential to be used to treat various conditions including cancer, sarcopenia, and aging-related illnesses.
• Kantam Bio, established in the United States, creates biomarkers to detect AKI and cancer in its early stages. KB-1801, the company's flagship medication candidate, is now in preclinical research for the prevention of acute renal damage following heart surgery. The medication prevents inflammation of the kidneys, lungs, and uterus by inhibiting the activation of the uridine diphosphate (UDP) glucose or P2Y14 receptor. In addition, the company is working on therapies and diagnostics for delayed graft function disease, cystic fibrosis, and female reproductive tract inflammatory illnesses.

Competitive Landscape

A wide number of firms are making major contributions to the growth of the renal cancer therapy industry. Manufacturers of kidney cancer diagnostic tools are collaborating with local health ministries and medical administrations to evaluate the treatment diagnosis's impact on kidney cancer patients. Medical organizations and worldwide pharmaceutical industry leaders are doubling down on the development of advanced kidney cancer diagnostics. Product innovation and continued R&D initiatives to create sophisticated technologies have assisted market expansion.

• Glenmark Pharma launched SUTIB, a generic kidney cancer medication, in India in February 2021. Sunitinib, an oral multikinase inhibitor (MKI), is beneficial in treating patients with gastrointestinal stromal tumors and advanced renal cell carcinoma. Sunitinib is an oral MKI that operates by inhibiting multiple enzymes that stimulate cell proliferation. It is also authorized for people suffering from specific types of pancreatic neuroendocrine tumors. The medicine is priced at Rs 7000 (50 mg), Rs 3600 (25 mg), and Rs 1840 (12.5 mg) each month, which is roughly 96% less than the MRP of the originator brand. The US Food and Drug Administration has also authorized sunitinib (US FDA).
• Cabolong, a marketed generic of Cabozantinib, was launched in September 2021 from MSN Labs for the treatment of renal cell carcinoma. Cabolong is produced at MSN Labs' facility, which has been authorized by strict worldwide regulatory agencies such as the US FDA and EU GMP.

Key Segments Profiled in the Kidney Cancer Diagnostics Market Study

• By Test :

  • Immunohistochemistry
  • Complete Blood Count
  • Urine Test
  • Blood Chemistry

• By Indication :

  • Renal Cell Carcinoma
  • Transitional Cell Carcinoma
  • Kidney Sarcoma
  • Wilms Tumor
  • Kidney Lymphoma

• By End User :

  • Hospital-associated Labs
  • Independent Diagnostic Laboratories
  • Cancer Research Institutes
  • Others

• By Region :

  • North America
  • Latin America
  • Europe
  • Japan
  • APEJ
  • Middle East Africa